4
H index
2
i10 index
52
Citations
Martina Garau : Citation Profile
Office of Health Economics | RESEARCH PRODUCTION: 1 Articles 25 Papers 1 Books RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
14 years (2006 - 2020). Relations with other researchers
Works with:
Authors registered in RePEc who have co-authored more than one work in the last five years with Martina Garau. | Is cited by:
| Cites to:
|
Main data
Where Martina Garau has published?
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Consulting Reports / Office of Health Economics | 13 |
| Research Papers / Office of Health Economics | 7 |
| Briefings / Office of Health Economics | 4 |
Recent works citing Martina Garau (2022 and 2021)
| Year | Title of citing document |
|---|---|
| 2021 | Overcoming inefficiencies in the development of personalized medicine. (2021). Wuttke, David A ; Heese, Sebastian H ; Lutkemeyer, Daniel. In: European Journal of Operational Research. RePEc:eee:ejores:v:290:y:2021:i:1:p:278-296. Full description at Econpapers || Download paper |
| 2021 | . Full description at Econpapers || Download paper |
| 2021 | Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?. (2021). Cubi-Molla, Patricia ; Devlin, Nancy ; Buxton, Martin. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:19:y:2021:i:5:d:10.1007_s40258-021-00648-2. Full description at Econpapers || Download paper |
| 2022 | Consideration of quality of life in the health technology assessments of rare disease treatments. (2022). Drummond, Michael ; Facey, Karen ; Upadhyaya, Sheela ; Whittal, Amanda ; Meregaglia, Michela ; Nicod, Elena. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:23:y:2022:i:4:d:10.1007_s10198-021-01387-w. Full description at Econpapers || Download paper |
| 2021 | The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment. (2021). Meregaglia, Michela ; Whittal, Amanda ; Nicod, Elena. In: The Patient: Patient-Centered Outcomes Research. RePEc:spr:patien:v:14:y:2021:i:5:d:10.1007_s40271-020-00493-w. Full description at Econpapers || Download paper |
| 2021 | Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis. (2021). Kim, Hansoo ; Liew, Danny ; Goodall, Stephen ; Cook, Greg . In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:5:y:2021:i:3:d:10.1007_s41669-021-00265-8. Full description at Econpapers || Download paper |
| 2021 | Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Per. (2021). Steier, Joerg S ; Blissett, Deirdre B ; Karagama, Yakubu G. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:5:y:2021:i:3:d:10.1007_s41669-021-00266-7. Full description at Econpapers || Download paper |
| 2021 | Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review. (2021). Campbell, Jonathan D ; Nemeth, Bertalan ; Elezbawy, Baher ; Mendola, Nicholas D ; Zelei, Tamas. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:5:y:2021:i:4:d:10.1007_s41669-021-00271-w. Full description at Econpapers || Download paper |
| 2022 | Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden. (2022). Heeg, B ; Ostby, Torup J ; Jakobsson, M ; Russell-Smith, T A ; Oostrum, I. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:6:y:2022:i:1:d:10.1007_s41669-021-00287-2. Full description at Econpapers || Download paper |
| 2021 | The economic theory of cost?effectiveness thresholds in health: Domestic and international implications. (2021). Hollis, Aidan ; Moradpour, Javad. In: Health Economics. RePEc:wly:hlthec:v:30:y:2021:i:5:p:1139-1151. Full description at Econpapers || Download paper |
Works by Martina Garau:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2009 | Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries In: Briefings. [Full Text][Citation analysis] | paper | 6 |
| 2007 | Estimating Pharmaceutical Companies Value to the Nation: Case Study of the British Pharma Group In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward In: Briefings. [Full Text][Citation analysis] | paper | 2 |
| 2019 | How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy In: Briefings. [Full Text][Citation analysis] | paper | 1 |
| 2011 | Exploring the Interdependency between Public and Charitable Medical Research In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2010 | Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2009 | Assessment and Appraisal of Oncology Medicines: NICEs Approach and International HTA Experience In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2006 | Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2014 | Obstructive Sleep Apnoea: Health Economics Report In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
| 2016 | Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Policy Options for Formulary Development in Middle-income Countries In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
| 2018 | Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
| 2019 | Unrelieved Pain in Palliative Care in England In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2020 | Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making? In: Consulting Reports. [Full Text][Citation analysis] | paper | 2 |
| 2020 | International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
| 2007 | European Medicines Pricing and Reimbursement: Now and the Future In: Monographs. [Full Text][Citation analysis] | book | 0 |
| 2011 | Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Papers. [Full Text][Citation analysis] | paper | 2 |
| 2013 | Exploring the link between health and wealth in decision making In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2013 | Multi-Criteria Decision Analysis to Value Orphan Medicines In: Research Papers. [Full Text][Citation analysis] | paper | 14 |
| 2012 | Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? In: Research Papers. [Full Text][Citation analysis] | paper | 5 |
| 2010 | Using QALYs in Cancer: Review of the Methodological Limitations In: Research Papers. [Full Text][Citation analysis] | paper | 12 |
| 2014 | Exploring the Interdependencies of Research Funders in the UK In: Research Papers. [Full Text][Citation analysis] | paper | 2 |
| 2016 | Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).(2018) In: PharmacoEconomics - Open. [Full Text][Citation analysis] This paper has another version. Agregated cites: 0 | article | |
| 2018 | R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C In: Research Papers. [Full Text][Citation analysis] | paper | 2 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated August, 1st 2022. Contact: CitEc Team